I wish vaccine will be Released as soon as it could be. Gloves demands will continue to rise even until the vaccines become available for the community. But before economy is fully recovered, invest in glove company will still be my pick during and even post pandemic.
This is so confusing...today all glove stock drop to the level on 17th August. 18th August everything rebound like crazy. With current sudden surge of covid19, will the miracle on 18th August occur again tomorrow? This is so difficult to decide for those who wants to sell and cut loss tomorrow, whether we should sell first thing in the morning or should keep? If keep but the miracles of 18th doesnt occur, we will cut loss more...
Not only glove sector but whole world market under big correction....crude oil price also plunging down...hope covid 19 related stocks such as glove and healthcare make a reversal soon to balance the bearish stock in other sectors...cheers
Table 2 – Top Global Manufacturers and Producers of Nitrile Gloves based on Industry Research’s 2019 Global Market research report Note – Annual revenue values derived from company websites and annual financial reports. Company Name Location Estimated Annual Revenue
AMMEX Kent, Washington, USA Privately held
Ansell Richmond, Australia $1.499 billion
Aurelia Gloves Aurora, IL, USA Privately held
Barber Healthcare Leyburn, United Kingdom Privately held
Comfort Rubber Gloves Industries Perak, Malaysia $109.8 million
Dynarex Orangeburg, NY, USA Privately held
Hartalega Holdings Kuala Lumpur, Malaysia $655 million
Illinois Glove Northbrook, IL, USA Privately held
Kimberly-Clark Irving, TX $18.45 billion
Kossan Rubber Selangor, Malaysia $492 million
Medicom Montreal, Canada Privately held
Renco Corporation Manchester, MA Privately held
Riverstone Selangor, Malaysia $211.8 million
Rubberex Perak, Malaysia $47.6 million
Semperit Vienna, Austria $925 million
Sempermed North Clearwater, FL, USA $925 million
Synthomer Essex, United Kingdom $1.81 billion
Tan Sin Lian Johor, Malaysia Privately held
Top Glove Shah Alam, Malaysia $1.1 billion
United Glove Newton, NC, USA Privately held
VWR Radnor, PA, USA $1.52 billion
YTY Group Kuala Lumpur, Malaysia $10.8 billion - include mother company group revenue.
In terms of an increase in global production, CGSCIMB in a recent report noted that China glove makers had announced aggressive expansion plans.
“Recent media reports indicate that two China glove makers, Blue Sail Medical and Intco Medical, have ambitious plans to ramp up their nitrile glove production capacity. We gather that Blue Sail aims to raise its nitrile glove production capacity to 36.1 billion by end-2023 from 4.3 billion at end-2019.
“Intco plans to expand its nitrile glove capacity to 59.2 billion per annum by end-2023 from five billion at end-2019.”
Has the euphoria for rubber glove makers dissipated? Wong Ee Lin / theedgemarkets.com
September 03, 2020 10:30 am +
Two other research houses have meanwhile downgraded the glove sector to "neutral" from "overweight".
JF Apex Securities Bhd attributed its decision to downgrade to the deceleration of new cases of COVID-19 and the faster-than-expected development of the vaccine.
Another reason, it said, was that the momentum of rising average selling price (ASP) for gloves might not be as strong as initially thought as more companies were venturing into the medical glove business.
Also, the demand for gloves was tapering as a result of less social activities, said JF Apex in a note on Aug 27.
AmInvestment Bank on Aug 25 also downgraded the glove sector to "neutral" as the research firm believed that the valuations for glove companies under its coverage had been fully priced in.
"We think that the ASP will begin to taper off in [the first quarter of] 2021 after the expected increase in ASP until end-2020, which has been priced in. Share prices of all of the glove companies in our coverage have exceeded their target prices," said AmInvestment.
China's CNBG, Sinovac find more countries to test Covid-19 vaccines Roxanne Liu & Tony Munroe / Reuters
September 05, 2020 19:39 pm
BEIJING (Sept 5): China National Biotec Group (CNBG) and Sinovac Biotech Ltd said on Saturday four more countries have agreed to run late-stage clinical tests of their coronavirus vaccine candidates, as China steps up its efforts in the global race.
Serbia and Pakistan are among the new countries agreeing to Phase 3 trials, as the two companies seek more data overseas amid dwindling new cases in China.
Serbia will test two vaccines developed by CNBG's Wuhan and Beijing units, and Pakistan will test the Beijing unit's candidate, the company told Reuters. CNBG's Phase 3 trials are expected to involve 50,000 people in about 10 countries, said CNBG vice president Zhang Yuntao. Trials have already begun in United Arab Emirates, Bahrain, Peru, Morocco, Argentina and Jordan.
Zhang said foreign countries have expressed interest in ordering a combined 500 million doses of its vaccines.
CNBG is expected to be able to produce 300 million doses of vaccine a year once it upgrades manufacturing techniques, and is working on a plan to raise its annual capacity to 1 billion doses, Zhang said.
Sinovac's vaccine candidate CoronaVac, being tested in Brazil and Indonesia, also obtained approvals from two other countries for Phase 3 trials, said Helen Yang, senior director of global strategy and business development at Sinovac.
@Mikecyc, I am not interested on K+ but since you have done extensive research on the market (or so it appears), could you please let us know which counter definitely will UUU today? TQIA
Late stage trials for the vaccine being developed by AstraZeneca and Oxford University have been put on hold A 'serious adverse event,' a possible reaction to the shot was reported in the UK It's not clear what happened to the individual, but an adverse event is considered 'serious' if it requires hospitalization, is life-threatening or deadly Stat News reported that the individual is expected to recover, but little else is known about their identity It is not clear if regulators, AstraZeneca or Oxford called for the trial hold The shot was dubbed the best hope for a vaccine by the WHO and is one of nine in phase three trials - the last tests before approval can be sought
so, since if even a qualified professional remisier could also be fined rm75k for deliberate stock market manipulation ...
then, random unlicensed unqualified guys should also be held even more responsible for indiscriminately dispensing inappropriate 'advice' or 'consultancy' with the suspected or likely intention of manipulating the stock market in the direction that they prefer or is favourable to them
Areca Capital Sdn Bhd chief executive officer Danny Wong Teck Meng said it is normal for investors to take profit on glove counters especially after the substantial gains in the past few months.
"When the prices keep on going up, there will be some profit-taking, so [a pullback of] anything between 15% and 20% is healthy.
"As we always look beyond the short term, I am pretty okay with glove counters' fundamentals as they are expected to continue to deliver good earnings in coming quarters. Hence, fundamentally speaking, I will still hold glove stocks," Wong added.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Mikecyc
45,161 posts
Posted by Mikecyc > 2020-09-08 21:04 |
Post removed.Why?